Floatz logo

Therapeutic Asset Ratings

9,920 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
nxp900
Non-Small Cell Squamous Lung Carcinoma
Nuvectis Pharma, Inc.P1CC (43)
Oatd-02
Ovarian Carcinoma
Molecure S.A.P1CC (43)
Oatd-02
Exocrine Pancreatic Carcinoma
Molecure S.A.P1CC (43)
Obecabtagene Autoleucel Chimeric Antigen Receptor
Chronic Progressive Multiple Sclerosis
Autolus LimitedP1CC (43)
Obinutuzumab
Urinary Bladder Carcinoma
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Cervical Squamous Cell Carcinoma
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Endometrial Carcinoma
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Estrogen-Receptor Positive Breast Cancer
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Esophageal Cancer
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Small Cell Lung Carcinoma
Chugai PharmaceuticalP1CC (43)
Obinutuzumab
Gastroesophageal Cancer
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Her2-Receptor Negative Breast Cancer
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Neoplasm Of Mature B-Cells
BeOne MedicinesP1CC (43)
Obinutuzumab
Mesothelioma
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Ovarian Cancer
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Pancreatic Adenocarcinoma
German Cancer Research CenterP1CC (43)
Obinutuzumab
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
National Cancer Institute (NCI)P1CC (43)
Obinutuzumab
Prostate Cancer
NeoTX Therapeutics Ltd.P1CC (43)
Obinutuzumab
Urothelial Carcinoma
NeoTX Therapeutics Ltd.P1CC (43)
Obx-115
Neoplasm
M.D. Anderson Cancer CenterP1CC (43)
Ocrelizumab
Autoimmune Disease
Indapta Therapeutics, INC.P1CC (43)
Ocrelizumab
CNS Demyelinating Autoimmune Disease
Indapta Therapeutics, INC.P1CC (43)
Ocrelizumab
Immune System Disorder
Indapta Therapeutics, INC.P1CC (43)
Ocrelizumab
Nervous System Disorder
Indapta Therapeutics, INC.P1CC (43)
Oct-598
Gastroesophageal Cancer
Oscotec Inc.P1CC (43)
Showing 3576 to 3600 of 9,920 assets
PreviousPage 144 of 397Next